Skip to Content
Merck

Murine xenograft bioreactors for human immunopeptidome discovery.

Scientific reports (2019-12-08)
James M Heather, Paisley T Myers, Feng Shi, Mohammad Ovais Aziz-Zanjani, Keira E Mahoney, Matthew Perez, Benjamin Morin, Christine Brittsan, Jeffrey Shabanowitz, Donald F Hunt, Mark Cobbold
ABSTRACT

The study of peptides presented by MHC class I and class II molecules is limited by the need for relatively large cell numbers, especially when studying post-translationally modified or otherwise rare peptide species. To overcome this problem, we pose the hypothesis that human cells grown as xenografts in immunodeficient mice should produce equivalent immunopeptidomes as cultured cells. Comparing human cell lines grown either in vitro or as murine xenografts, we show that the immunopeptidome is substantially preserved. Numerous features are shared across both sample types, including peptides and proteins featured, length distributions, and HLA-binding motifs. Peptides well-represented in both groups were from more abundant proteins, or those with stronger predicted HLA binding affinities. Samples grown in vivo also recapitulated a similar phospho-immunopeptidome, with common sequences being those found at high copy number on the cell surface. These data indicate that xenografts are indeed a viable methodology for the production of cells for immunopeptidomic discovery.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Aprotinin from bovine lung, lyophilized powder, 3-7 TIU/mg solid
Sigma-Aldrich
Leupeptin, microbial, ≥90% (HPLC)
Sigma-Aldrich
Pepstatin A, ≥100,000 U/mg